Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
The latest available 13F covers holdings as of Jun 30, 2026 (Q2 2026) and was filed Aug 14, 2026. Quarter-end snapshot, not a live trade.
Disclosed 13F value
$6.65B
sum of reported positions
Reported positions
108
Changes vs prior quarter
96
29 new · 14 exited
Filings on record
9
Q2 2026, Q1 2026, Q4 2025, Q3 2025, Q2 2025, Q1 2025, Q4 2024, Q3 2024, Q2 2024
Across 138 measured positions in 8 quarters, the typical new or larger position finished −0.1 pts against the S&P 500 and 50% finished ahead of it. For scale, across all 501 funds with a result: −2.2 pts typical, 44% ahead.
Measured on each position this fund reported as new or larger, from the first close after the filing became public, against the S&P 500, 90 days later. Sales are not scored. History, not a forecast; it shows what the stocks did, not what the fund knew.
Total value of the 13F each quarter. It moves with prices as well as with what the fund bought or sold, so a rise is not necessarily a purchase.
| Company | Shares | Value | Weight |
|---|---|---|---|
| 2.04M | $682M | 10.3% | |
| 4.32M | $383M | 5.8% | |
| 3.2M | $334M | 5.0% | |
Comparison uses this manager's immediately preceding 13F-HR. Puts and calls are separate lines. Share counts drive classification; reported value also moves with price.Methodology
Change in the reported value against the quarter before.
Weights are within the disclosed 13F portfolio, for the ten largest lines.
| Q1 2026 | Q2 2026 | |
|---|---|---|
| Reported value | $5.1B | $6.65B |
| Positions | 93 | 108 |
| Biggest line | — | Praxis Precision Medicines 10% |
| 1.16M |
| $310M |
| 4.7% |
| 2.59M | $287M | 4.3% |
| 8.09M | $286M | 4.3% |
| 14.1M | $264M | 4.0% |
| 3.75M | $213M | 3.2% |
| 8.2M | $196M | 2.9% |
NUVALENT INC | 1.58M | $195M | 2.9% |
| 4.37M | $178M | 2.7% |
APOGEE THERAPEUTICS INC | 1.31M | $174M | 2.6% |
| 8.33M | $150M | 2.3% |
| 10.8M | $146M | 2.2% |
| 1.35M | $128M | 1.9% |
| 1.3M | $123M | 1.8% |
| 982K | $120M | 1.8% |
| 11.9M | $119M | 1.8% |
| 4.18M | $109M | 1.6% |
| 3.38M | $106M | 1.6% |
| 10.4M | $105M | 1.6% |
| 4.32M | $105M | 1.6% |
| 10.3M | $103M | 1.6% |
| 528K | $98.8M | 1.5% |
| 2.68M | $88.1M | 1.3% |
Outlook Therapeutics (OTLK)
3.14M shares
Avalo Therapeutics (AVTX)
140K → 220K shares (+57%)
Twist Bioscience (TWST)
150K → 37K shares (−76%)
Xeris Biopharma Holdings (XERS)
467K shares
Biodesix (BDSX)
109K shares
Kiora Pharmaceuticals (KPRX)
438K shares
ADMA Biologics, Inc. (ADMA)
467K → 114K shares (−76%)
ENGENE HOLDINGS INC
5.83M shares in Q1 2026
CENTESSA PHARMACEUTICALS PLC
5.26M shares in Q1 2026
Neumora Therapeutics (NMRA)
5.1M shares in Q1 2026
Inhibikase Therapeutics (IKT)
2.31M shares in Q1 2026
Opus Genetics (IRD)
1.84M shares in Q1 2026
DAY ONE BIOPHARMACEUTICALS I
1.76M shares in Q1 2026
ASCENDIS PHARMA A/S
1.53M shares in Q1 2026
Ocular Therapeutix (OCUL) · CALL
500K shares in Q1 2026
Evommune (EVMN)
448K shares in Q1 2026
Bright Minds Biosciences (DRUG)
378K shares in Q1 2026
Belite Bio (BLTE)
152K shares in Q1 2026
APELLIS PHARMACEUTICALS INC
81K shares in Q1 2026
Neurocrine Biosciences (NBIX)
65K shares in Q1 2026
Palatin Technologies (PTN)
62K shares in Q1 2026
